From insights to impact: The evolving rare disease landscape in 2025 and beyond
About the webinar
In honor of Rare Disease Month, experts from Sanofi, Novartis, and Definitive Healthcare explore how the rare disease space has evolved and where it is heading in 2025. This roundtable provides key insights into how breaking down data silos, fostering collaboration, and focusing on rare diseases within the broader pharma ecosystem can accelerate the development of life-changing therapies.
In this session we will:
- Share how integrated data from clinical trials and real-world sources can improve drug development and trial design and address unmet needs in rare diseases.
- Explore how collaboration between pharma, healthcare providers, academics, and patient groups is key to advancing research and improving patient access to therapies.
- Discuss how a growing focus on rare diseases, alongside better data access, will shape drug development, personalized medicine, and patient care in the coming years.
Our speakers
Alex Paragios
Strategic Account Director, SanofiAlex Paragios has been with Sanofi for 11+ years. In his role, he serves as the Regional Business Director – Northeast.
Brian Garino
Director, Advanced Analytics, NovartisBrian Garino is the Director, Advanced Analytics at Novartis. In his role, he leads predictive analytics practice designed to drive commercial acceleration via personal and digital touch optimization.
Evan Raggi
Principal, Definitive HealthcareEvan Raggi brings 15+ years of data and analytics experience across cpg and healthcare companies. From start-ups to Fortune 100 companies, Evan has worked for some of the brightest and most innovative companies. At Definitive Healthcare, Evan partners with our largest biopharma clients to help problem-solve, leveraging our entire portfolio of products and services.
Rohit Marwah
AVP, Insights and Analytics, Definitive HealthcareRohit Marwah is a seasoned real-world data specialist and subject matter expert within the pharmaceutical, payer, and provider domains. With a background spanning over 15 years, he has spearheaded numerous sophisticated data analytics initiatives, shaping commercial, HEOR, payer, and provider strategies through the utilization of real-world evidence, social, and publication data.